Genmab, Novo Nordisk deal

Genmab granted Novo exclusive, worldwide rights to use Genmab’s DuoBody technology to develop and commercialize bispecific antibodies against undisclosed targets for two indications, excluding cancer. After an initial period, Novo has an option to maintain exclusivity for the technology. The DuoBody technology generates bispecific IgG1 antibodies based on Fab-arm exchange. ...